4.7 (12)
Mayzent (siponimod) significantly improved cognitive processing speed in people with secondary progressive multiple sclerosis (SPMS) compared with a placebo, according to additional analyses of two-year data from the EXPAND Phase 3 trial.
While no approved therapies in the U.S. currently target cognitive impairment in MS, “our study found that [Mayzent], which is prescribed to slow the progression of physical disability in MS, may also help improve cognitive processing speed in people with advanced MS,” Ralph H. B. Benedict, PhD, the study’s first author, said in a press release.
Benedict is a professor of neurology at the University of Buffalo in New York, and a member of the American Academy of Neurology.